Updated overview of first-line treatment for diffuse large B-cell non-Hodgkin lymphoma

Abstract

The therapeutic approach to Diffuse Large B-Cell Lymphoma (DLBCL) is based on the curative intent of the treatment regardless of its clinical stage and the presence of poor prognostic factors. Chemoimmunotherapy remains the standard treatment, with or without radiation therapy. Monoclonal antibodies have shown significant improvement in survival and are currently being incorporated into first-line treatment at the onset of the disease. Novel therapies have shown encouraging results for the first line, however data still immature and not yet better than the standard of care. Remarkably, first-line treatment involves certain considerations that we should take into account in clinical situations such as older age, pregnancy, HIV infection, resected and extranodal disease.